ICKSMCB 2022 / 2022 International Conference of the Korean Society for Molecular and Cellular Biology / September 28 - 30, 2022 / ICC JEJU

Nobel Laureate Lecture

HOME > Program > Luncheon Symposium

Cytiva



September 29(Thu), 13:05-13:30(25min.), 1F Yeongju Hall B

Lee Young

Sera-Mag™ mag-bead cell free DNA liquid biopsy for monitoring cancer-associated mutations in NSCLC patients

Young Lee, Ph.D.
Diagnostics Design-in Field Application Scientist, Cytiva

Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality worldwide as the diagnosis is often made at the very late stage. Current guidelines advocate the use of molecular profiling in the evaluation of genetic drivers in NSCLC and the use of cell free DNA (cfDNA) -based profiling from patients with insufficient tissue. An extraction system that allows for the enrichment of small-bp, tumor-associated cfDNA fragments while effectively eliminating the contamination of high molecular weight genomic DNA would be advantageous for the cfDNA-based profiling. Here, Cytiva presents Sera-Xtracta™ cfDNA extraction kit and its application on the genetic monitoring of NSCLC patient. Utilization of Sera-Xtracta™ cfDNA kit in targeted NGS displayed the highest detection of mutation allele frequency (MAF) and identified mutations in BRAF and TP53 genes of the patients. The genetic monitoring of 3 NSCLC patients with different therapies was conducted with cfDNA-based ddPCR and targeted NGS. The genetic profiling of EGFR mutations in the clinically relevant setting highlighted that the quality of cfDNA extraction can impact the sensitivity of biomarker detection and ultimately on patient outcomes. The latter part of this presentation introduces Cytiva’s various solutions for diagnostic technologies.